Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies

Here we report the sensitivity of emerging omicron sublineages BA.2.75.2, BA.4.6, and BA.2.10.4 to neutralisation by a panel of clinically relevant and preclinical monoclonal antibodies and by serum from blood donated in Stockholm, Sweden. To characterise the evolving resistance to immunity at the population level, we evaluated the sensitivity to neutralisation by serum from random blood donors in Stockholm, including a cohort sampled Nov 8–14, 2021 (November 2021 cohort; figure C), before the emergence of the omicron variant; a cohort sampled April 11–17, 2022 (April 2022 cohort; figure D), after both a large wave of infections (driven by BA.1 then BA.2) and the rollout of third vaccine doses; and a cohort sampled Aug 29 to Sept 4, 2022 (September 2022 cohort; figure E), after the spread of BA.5. Taken together, these data identify profound antibody escape by the emerging omicron sublineage BA.2.75.2, suggesting that it effectively evades current humoral immunity in the population.